{"entity":{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","aka":["VICC"],"tldr":"Tennessee's NCI comprehensive centre, birthplace of the My Cancer Genome knowledge base and the molecular subtypes of triple-negative breast cancer.","summary":"NCI-designated in 1995 and comprehensive since 2001, Vanderbilt-Ingram serves Tennessee and the mid-South. William Pao, who had discovered the EGFR T790M resistance mutation, launched My Cancer Genome here in 2011, one of the first public precision-oncology knowledge bases. Brian Lehmann and Jennifer Pietenpol defined the molecular subtypes of triple-negative breast cancer, Justin Balko studies immunotherapy in TNBC, and Douglas Johnson's work on immune-related adverse events shaped their management. The Southern Community Cohort Study, run from Vanderbilt, is a major resource on cancer disparities in the South. Kimryn Rathmell moved from chairing medicine here to directing the NCI in 2023.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Vanderbilt-Ingram_Cancer_Center","links":[{"label":"Vanderbilt-Ingram Cancer Center","url":"https://www.vicc.org"},{"label":"Clinical trials","url":"https://www.vicc.org/clinical-trials"},{"label":"My Cancer Genome","url":"https://www.mycancergenome.org"}],"tags":[],"related":[],"cancers":["tnbc","nsclc","melanoma","colorectal"],"sections":[],"technologies":["cgp"],"targets":["egfr","pik3ca"],"drugs":["osimertinib"],"companies":[],"institutions":["nci"],"pathways":[],"terms":["irae"],"trials":[],"people":["martha-ingram","brian-rini"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nashville, TN","country":"US","lat":36.141,"lng":-86.803,"institutionType":"cancer-center","website":"https://www.vicc.org","nci":"comprehensive","university":"Vanderbilt University","programs":["Precision oncology (My Cancer Genome)","TNBC subtypes","Immune-related adverse events","Southern Community Cohort"]},"route":"/institutions/vanderbilt-ingram/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/"}],"person":[{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/"},{"id":"martha-ingram","kind":"person","name":"Martha Rivers Ingram","route":"/people/martha-ingram/"}],"bottleneck":[{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}],"paper":[{"id":"paper-lehmann-tnbc-subtypes-jci-2011","kind":"paper","name":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","route":"/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/"},{"id":"paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021","kind":"paper","name":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","route":"/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/"},{"id":"paper-lehmann-tnbctype-4-refinement-plos-one-2016","kind":"paper","name":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","route":"/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/"},{"id":"paper-kris-lung-cancer-mutation-consortium-jama-2014","kind":"paper","name":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","route":"/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/"}]}}